A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)
Phase 3 Open-label, Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure) - an Investigation of the Safety of Treatment Beyond 7 Days and the Effect of Dose Escalation to 30 mg